Sage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Sage Therapeutics (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Sage Therapeutics Price Performance

NASDAQ:SAGE traded down $0.07 during trading hours on Tuesday, hitting $7.19. 2,062,956 shares of the company were exchanged, compared to its average volume of 2,503,787. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $27.39. The stock has a market capitalization of $439.81 million, a price-to-earnings ratio of -1.29 and a beta of 0.94. The company’s 50 day moving average price is $6.25 and its 200-day moving average price is $6.98.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SAGE shares. Stifel Nicolaus cut their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a report on Monday, December 16th. HC Wainwright reissued a “neutral” rating and set a $14.00 target price on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Oppenheimer dropped their target price on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. Truist Financial decreased their price objective on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, October 30th. Finally, Scotiabank decreased their price objective on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating for the company in a report on Wednesday, October 30th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.53.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.